Research Update
Pimavanserin Moves Toward First-Line Use for Parkinson's Psychosis
Compiled by Carlat Editorial Staff and Reviewed by the Editor-in-Chief and the Editorial Board.
Staff members have no financial relationships with companies related to this material.
